Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew D. Goodman, Rachel Farrell, Raymond Hupperts, Andrew R. Blight, Veronica Englishby, Manjit McNeill, Ih Chang, Gabriel Lima, Jacob Elkins, Unknown

Open source

DOI: 10.1007/s40263-018-0586-5
Published: 2018-12-10
Container: CNS Drugs
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40263-018-0586-5,
  title = {Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine},
  author = {Jeremy Hobart and Tjalf Ziemssen and Peter Feys and Michael Linnebank and Andrew D. Goodman and Rachel Farrell and Raymond Hupperts and Andrew R. Blight and Veronica Englishby and Manjit McNeill and Ih Chang and Gabriel Lima and Jacob Elkins and Unknown},
  year = {2018},
  journal = {CNS Drugs},
  doi = {10.1007/s40263-018-0586-5},
  url = {https://doi.org/10.1007/s40263-018-0586-5}
}

RIS

TY  - JOUR
TI  - Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
AU  - Jeremy Hobart
AU  - Tjalf Ziemssen
AU  - Peter Feys
AU  - Michael Linnebank
AU  - Andrew D. Goodman
AU  - Rachel Farrell
AU  - Raymond Hupperts
AU  - Andrew R. Blight
AU  - Veronica Englishby
AU  - Manjit McNeill
AU  - Ih Chang
AU  - Gabriel Lima
AU  - Jacob Elkins
AU  - Unknown
PY  - 2018
JO  - CNS Drugs
DO  - 10.1007/s40263-018-0586-5
UR  - https://doi.org/10.1007/s40263-018-0586-5
ER  -

APA

Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A. D., Farrell, R., Hupperts, R., Blight, A. R., Englishby, V., McNeill, M., Chang, I., Lima, G., Elkins, J., & Unknown (2018). Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. CNS Drugs. https://doi.org/10.1007/s40263-018-0586-5

Source records

crossref · retrieved 2026-09-27T02:01:20.323Z